Enhanced cerebral uptake of receptor ligands by modulation of P- glycoprotein function in the blood-brain barrier

Synapse

Volumn 36, Issue 1, 2000, Pages 66-74

  Doze, P ^a   Van Waarde, A ^a   Elsinga, P H ^a   Hendrikse, N H ^a   Vaalburg, W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

adrenoceptors; Blood brain barrier; P glycoprotein; PET

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR; CARAZOLOL; CYCLOSPORIN A; GLYCOPROTEIN P; LIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DRUG BINDING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CARBAZOLES; CYCLOSPORINE; FLUORINE RADIOISOTOPES; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROPANOLAMINES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034051677     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(200004)36:1<66::AID-SYN7>3.0.CO;2-J     Document Type: Article

References (31)

1. Begley DJ. 1992. The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs. Prog Brain Res 91:163-169.
2. Berridge MS, Cassidy EH, Terris AH, Vesselle JM. 1992. Preparation and in vivo binding of [11C]carazolol, a radiotracer for the beta-adrenergic receptor. Nucl Med Biol 19:563-569.
3. Bradbury MW. 1985. The blood-brain barrier. Transport across the cerebral endothelium. Circ Res 57:213-222.
4. Cefalu WT, Pardridge WM. 1985. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. J Neurochem 45:1954-1956.
5. Cordon CC, O'Brien JP, Casals D, Rittman GL, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
6. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. 1996. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179.
7. Dischino DD, Welch MJ, Kilbourn MR, Raichle ME. 1983. Relationship between lipophilicity and brain extraction of C-11 labeled radiopharmaceuticals. J Nucl Med 24:1030-1038.
8. Doze P, van-Waarde A, Elsinga PH, Weemaes AMA, Willemsen AT, Vaalburg W. 1998. Validation of s-1′-[F-18]Fluorocarazolol for in vivo imaging and quantification of cerebral beta-adrenoceptors. Eur J Pharmacol 353:215-226.
9. Elsinga PH, Vos MG, Van Waarde A, Braker AH, De Groot TJ, Anthonio RL, Weemaes AMA, Brodde OE, Visser GM, Vaalburg W. 1996. (S,S)- and (S,R)-1′-[18F]fluorocarazolol, ligands for the visualization of pulmonary β-adrenergic receptors with PET. Nucl Med Biol 23:159-167.
10. Elsinga P, van-Waarde A, Doze P, Visser TJ, Heldoorn M, Jaeggi KA, Vaalburg W. 1997. One-pot synthesis of [11C]-labelled beta-adrenergic ligands from [11C]acetone. J Label Compds Radiopharm (Abstract) 40:595-597.
11. Grimm LJ, Blendy JA, Kellar KJ, Perry DC. 1992. Chronic reserpine administration selectively up-regulates beta 1- and alpha 1b-adrenergic receptors in rat brain: an autoradiographic study. Neuroscience 47:77-86.
12. Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM, Vaalburg W, Franssen EJF. 1998. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
13. Innis RB, Correa FMA, Snyder SH. 1979. Carazolol, an extremely potent β-adrenergic blocker: binding to β-receptors in brain membranes. Life Sci 24:2255-2264.
14. Jette L, Murphy GF, Leclerc JM, Beliveau R. 1995. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50:1701-1709.
15. Karlsson J, Kuo SM, Ziemniak J, Artursson P. 1993. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016.
16. Kuo SM, Whitby BR, Artursson P, Ziemniak JA. 1994. The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm Res 11:648-653.
17. Lemaire M, Bruelisauer A, Guntz P, Sato H. 1996. Dose-dependent brain penetration of SDZ PSC 833, a novel multirirug resistance-reversingcyclosporin, in rats. Cancer Chemother Pharmacol 38:481-486.
18. Levin VA. 1980. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682-684.
19. McMillan MA. 1989. Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 42:135-156.
20. Moerlein SM, Laufer P, Stocklin G. 1985. Effect of lipophilicity on the in vivo localization of radiolabelled spiperone analogues. Int J Nucl Med Biol 12:353-356.
21. Schinkel AH, Smit JJ, van-Tellingen O, Beijnen JH, Wagenaar E, van-Deemter L, Mol CA, van der Volk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. 1994. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
22. Schinkel AH, Wagenaar E, Mol CA, van-Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
23. Shah MV, Audus KL, Borchardt RT. 1989. The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharm Res 6:624-627.
24. Staehelin M, Simons P, Jaeggi K, Wigger N. 1983. CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258:3496-3502.
25. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S. 1988. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48:1926-1929.
26. Taylor DC, Pownall R, Burke W. 1985. The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity. J Pharm Pharmacol 37:280-283.
27. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. 1996. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083-1089.
28. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
29. van-Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van-Tellingen O. 1996. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 88:994-999.
30. van-Waarde A, Visser TJ, Elsinga PH, de-Jong B, van-der-Mark TW, Kraan J, Ensing K, Pruim J, Willemsen AT, Brodde OE, Visser GM, Paans AM, Vaalburg W. 1997. Imaging beta-adrenoceptors in the human brain with (S)-1′-[18F]fluorocarazolol. J Nucl Med 38:934-939.
31. Zheng LB, Berridge MS, Ernsberger P. 1994. Synthesis, binding properties, and 18F labeling of fluorocarazolol, a high-affinity β-adrenergic receptor antagonist. J Med Chem 37:3219-3230.